Abstract
Mixed-lineage leukemia (MLL)/AF4-positive ALL is associated with a poor prognosis even after allogeneic hematopoietic SCT (allo-HSCT). We reported previously that MLL/AF4-positive ALL shows resistance to TNF-α, which is the main factor in the GVL effect, by upregulation of S100A6 expression followed by interference with the p53–caspase 8–caspase 3 pathway in vitro. We examined whether inhibition of S100A6 can induce an effective GVL effect on MLL/AF4-positive ALL in a mouse model. MLL/AF4-positive ALL cell lines (SEM) transduced with lentiviral vectors expressing both S100A6 siRNA and luciferase (SEM-Luc-S100A6 siRNA) were produced. SEM-Luc-S100A6 siRNA cells and SEM-Luc-control siRNA cells were injected into groups of five SCID mice (1 × 107/body). After confirmation of engraftment of SEM cells by in vivo imaging, the mice in each group were injected with 4.8 × 107 human PBMCs. SEM-Luc-S100A6 siRNA-injected mice showed significantly longer survival periods than SEM-Luc-control siRNA-injected mice (P=0.002). SEM-Luc-S100A6 siRNA-injected mice showed significantly slower tumor growth than those injected with SEM-Luc-control siRNA (P<0.0001). These results suggested that inhibition of S100A6 may be a promising therapeutic target for MLL/AF4-positive ALL in combination with allo-HSCT.
Similar content being viewed by others
References
Harper DP, Aplan PD . Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects. Cancer Res 2008; 68: 10024–10027.
Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909–1915.
Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M . The allogeneic graft-versus-cancer effect. Br J Haematol 2009; 147: 614–633.
Tamai H, Miyake K, Yamaguchi H, Takatori M, Dan K, Inokuchi K et al. Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulation. Blood Cancer J 2011; 1: e38.
Słomnicki ŁP, Nawrot B, Leśniak W . S100A6 binds p53 and affects its activity. Int J Biochem Cell Biol 2009; 41: 784–790.
van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR . Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem 2009; 284: 13804–13811.
Tsoporis JN, Izhar S, Parker TG . Expression of S100A6 in cardiac myocytes limits apoptosis induced by tumor necrosis factor-alpha. J Biol Chem 2008; 283: 30174–30183.
van Dieck J, Brandt T, Teufel DP, Veprintsev DB, Joerger AC, Fersht AR . Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73. Oncogene 2010; 29: 2024–2035.
Tamai H, Miyake K, Yamaguchi H, Takatori M, Dan K, Inokuchi K et al. AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice. Blood 2012; 119: 64–71.
Miyake K, Flygare J, Kiefer T, Utsugisawa T, Richter J, Ma Z et al. Development of cellular models for ribosomal protein S19(RPS19)-deficient diamond-blackfan anemia using inducible expression of siRNA against RPS19. Mol Ther 2005; 11: 627–637.
Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177–185.
Spijkers-Hagelstein JA, Schneider P, Hulleman E, de Boer J, Williams O, Pieters R et al. Elevated S100A8/S100A9 expression causes glucocorticoidresistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia 2012; 26: 1255–1265.
Pui CH, Relling MV, Downing JR . Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548.
Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189–3197.
Pui CH, Kane JR, Crist WM . Biology and treatment of infant leukemias. Leukemia 1995; 9: 762–769.
Pui CH, Ribeiro RC, Campana D, Raimondi SC, Hancock ML, Behm FG et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia 1996; 10: 952–956.
Eden TO, Pieters R, Richards S . Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children. Br J Haematol 2010; 149: 722–733.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Authorship
HT designed and conducted and performed the research, and wrote the paper. KM, HY, KD, TS and KI partially conducted the research.
Rights and permissions
About this article
Cite this article
Tamai, H., Miyake, K., Yamaguchi, H. et al. Inhibition of S100A6 induces GVL effects in MLL/AF4-positive ALL in human PBMC-SCID mice. Bone Marrow Transplant 49, 699–703 (2014). https://doi.org/10.1038/bmt.2014.18
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2014.18
- Springer Nature Limited
Keywords
This article is cited by
-
S100A6 is a critical regulator of hematopoietic stem cells
Leukemia (2020)
-
Chemotactic effect of S100A8 and S100A9 on human eosinophilic leukemia cells, EoL-1 through TLR4
Molecular & Cellular Toxicology (2018)
-
S100A6 protein: functional roles
Cellular and Molecular Life Sciences (2017)